title: Tumour angiogenesis: the relevance to surgeons.
abstract: BACKGROUND
  Angiogenesis is the process of new blood vessel formation from pre-existing vessels, and is a key feature of malignant tumours. Surgeons involved in the management of patients with malignant disease need to be aware of angiogenic mechanisms and their surgical implications.
  
  
  METHODS
  A literature search was used to review recent developments in our understanding of the factors and processes involved in tumour angiogenesis, and how these will impact on the care of patients with malignant disease encountered by surgeons.
  
  
  RESULTS
  Angiogenesis is fundamental to all stages of the malignant process, and involves a complex interaction between mediators secreted by tumour cells and host cells. Intense investigation continues into therapies targeting components of the angiogenic cascade. Imaging modalities capable of measuring the angiogenic activity of a tumour are also being studied in order to predict prognosis and select suitable patients for anti-angiogenic therapy.
  
  
  CONCLUSIONS
  As the use of these anti-angiogenic therapies becomes more wide-spread, they may have implications on the healing rates of cutaneous wounds and intracorporeal anastomoses.
authors.affiliation: Department of Surgery, Ealing Hospital NHS Trust, Middlesex, UK.
authors.forename: G K
authors.initials: GK
authors.lastname: Atkin
authors.forename: A
authors.initials: A
authors.lastname: Chopada
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009362:Neoplasm Metastasis / Q000503:physiopathology*; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D011183:Postoperative Complications / Q000209:etiology* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors